CUMBERLAND, R.I.--(BUSINESS WIRE)--Onset Dermatologics, a leader in developing and commercializing prescription products for improving skin health, today announced the acquisition of Clindagel® from Galderma Laboratories. Clindagel® is a prescription topical antibiotic for the treatment of acne. “Onset Dermatologics is pleased to add Clindagel® to our portfolio of acne products,” said Robert Moccia, President, Onset Dermatologics. “As a company, we are committed to providing products to help dermatology practitioners improve outcomes in their patients.” Clindagel® is the only topical formulation of clindamycin phosphate with once daily dosing approved by the U.S. Food and Drug Administration. In a 12-week multicenter, randomized, blinded, vehicle-controlled clinical trial in which patients used Clindagel® or its vehicle gel in the treatment of acne of mild-to-moderate severity, Clindagel® applied once daily was more effective than the vehicle. The mean percentage reduction in acne inflammatory lesion counts at the end of the study was 51% with Clindagel® vs. 40% with the vehicle. In addition, Clindagel® was well tolerated and demonstrated side effect profile similar to the water-based placebo gel vehicle alone.
Help employers find you! Check out all the jobs and post your resume.
